.jpeg)
Stocks Market
Laprophan Unveils $37M State-of-the-Art Injectable Manufacturing Facility Ahead of IPO
As Laprophan prepares for its Casablanca Stock Exchange debut, the pharmaceutical giant has showcased its ambitious industrial expansion. The company revealed a cutting-edge sterile injectable production facility through its Amanys Pharma subsidiary, representing a 374 million dirham investment near Rabat. Set to begin operations in 2027, this highly automated plant will produce 30 million consumer units annually, positioning Laprophan to strengthen its hospital pharmaceuticals portfolio and expand into African and European markets.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
In a strategic move coinciding with its stock market listing, Laprophan has unveiled the industrial capabilities of its Amanys Pharma subsidiary. The pharmaceutical group has invested 374 million dirhams in a sterile injectable production unit located in Aïn El Aouda, near Rabat, with operations scheduled to commence in 2027.
Massive Investment in Advanced Manufacturing Infrastructure
On Wednesday, November 11th, as its Casablanca Stock Exchange listing progressed, Laprophan presented its new sterile injectable production facility. The state-of-the-art installation spans 18,000 square meters of built space and represents a significant milestone in Morocco's pharmaceutical manufacturing landscape.
The highly automated facility boasts an annual production capacity of approximately 30 million consumer units. After nearly four years of design and construction, the plant is engineered to manufacture large-volume injectable medicines packaged in bottles and flexible bags. The complex also features storage capacity for 7,000 pallets, ensuring efficient inventory management.
EU Standards and Automated Systems
Built to European Good Manufacturing Practice (EU-GMP) standards, the facility incorporates automated processes and closed systems designed to minimize contamination risks—a critical requirement in sterile medicine production. According to Mohammed Squalli Houssaini, Deputy General Manager and Responsible Pharmacist at Amanys Pharma, the installations are now industrially ready.
The primary objective is to supply the Moroccan market while developing export channels, particularly targeting Africa and Europe. This strategic positioning aligns with Morocco's growing role as a pharmaceutical manufacturing hub for the region.
Expanded Antibiotic Production Capabilities
The Aïn El Aouda complex extends beyond injectables. Situated on a 62,000 square meter plot, the site also houses a specialized unit for manufacturing beta-lactam antibiotics in solid oral forms.
This antibiotic facility, covering 7,300 square meters, currently produces 15 million consumer units annually. Production capacity is projected to reach 25 million units by 2027, with storage capacity for 2,000 pallets.
Strategic Acquisition Strengthening Hospital Portfolio
Laprophan acquired 100% of Amanys Pharma in 2024 through AIF Pharma Maroc. The subsidiary plays a crucial role in the group's hospital activities, with a portfolio covering anti-infectives, intensive care, hematology, and specialized oncology.
Moulay Younous Elalamy, Administrator at Amanys Pharma, indicated that the large-volume injectable unit represents the first phase, with the group planning to develop small-volume injectable manufacturing capabilities as well.
IPO Context and Growth Strategy
This facility presentation comes at a pivotal moment for Laprophan, which is conducting an initial public offering valued at up to 2.22 billion dirhams. The operation, approved by Morocco's capital markets authority (AMMC) on October 28th, includes a capital increase of nearly 1.4 billion dirhams and existing share sales of approximately 822.56 million dirhams.
The subscription period, which opened on November 9th, continues through November 17th, 2026, at a price of 341 dirhams per share.
Company Profile and Regional Presence
Founded in 1949, Laprophan employs nearly 1,450 people. The group markets its medicines directly or indirectly in over 50 countries and maintains operational subsidiaries in eight nations.
With the anticipated commissioning of the new Amanys Pharma unit, Laprophan aims to expand its hospital medicine offerings, particularly in the sterile injectable segment, reinforcing its position as a leading pharmaceutical manufacturer in North Africa and beyond.